CHICAGO, IL—A novel CRISPR/Cas-9-based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin (ATTR) amyloidosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results